Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | TLR2 | O60603 | 4/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7752815 | 0.86 | KMT2A (0.67) | KMT2ATLR2CASP3 | |
| SCHEMBL15669323 | 0.85 | KMT2A (0.68) | KMT2ATLR2CASP3EPHX2 | |
| SCHEMBL28823765 | 0.85 | KMT2A (0.68) | KMT2ATLR2CASP3EPHX2 | |
| SCHEMBL14020667 | 0.84 | CETP (0.58) | KMT2ATLR2 | |
| SCHEMBL13295942 | 0.83 | KMT2A (0.64) | KMT2ATLR2CASP3EPHX2 | |
| SCHEMBL29401003 | 0.83 | KMT2A (0.51) | KMT2ACASP3EPHX2 | |
| SCHEMBL29367499 | 0.83 | KMT2A (0.51) | KMT2ACASP3EPHX2 | |
| SCHEMBL15087402 | 0.83 | KMT2A (0.51) | KMT2ACASP3EPHX2 | |
| SCHEMBL20371129 | 0.83 | KMT2A (0.51) | KMT2ACASP3EPHX2 | |
| SCHEMBL15669252 | 0.82 | KMT2A (0.64) | KMT2ATLR2CASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622572-B1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-3231445-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3222294-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2415486-B1 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-8461313-B2 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120202983-A1 | Conjugates and Compositions for Cellular Delivery | SIRNA THERAPEUTICS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8188247-B2 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2415486-A2 | Conjugates and compositions for cellular delivery | Sirna Therapeutics, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-7964578-B2 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20110124853-A1 | Conjugates and Compositions for Cellular Delivery | CHEN TONGQIAN | 2011-05-26 | — | — | US | disclosed |
| US-20090264636-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| EP-1572067-A4 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS INC (US) | 2009-05-13 | — | — | EP | disclosed |
| US-7491805-B2 | Biological conjugates used for drug delivery; side effect reduction | SIRNA THERAPEUTICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7109165-B2 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1622572-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1572067-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005041859-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY. | SIRNA THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20040110296-A1 | biological conjugates used for drug delivery; side effect reduction | RIBOZYME PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | disclosed |
| US-20030104985-A1 | Conjugates and compositions for cellular delivery | BANK OF AMERICA, N.A. | 2003-06-05 | — | — | US | disclosed |
| WO-2002094185-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124853-A1 | Conjugates and Compositions for Cellular Delivery | ALB, PHAX, HEXA | KMT2A 1090/4885TLR2 2142/4885CASP3 3508/4885 |
| US-20030104985-A1 | Conjugates and compositions for cellular delivery | MTHFD1, FOLR1, FOLR2 | KMT2A 1665/4885TLR2 4160/4885CASP3 2132/4885 |
| US-20120202983-A1 | Conjugates and Compositions for Cellular Delivery | MTHFD1, FOLR1, FOLR2 | KMT2A 1665/4885TLR2 4160/4885CASP3 2132/4885 |
| US-20090264636-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | ALB, PHAX, HEXA | KMT2A 1090/4885TLR2 2142/4885CASP3 3508/4885 |
| US-20040110296-A1 | biological conjugates used for drug delivery; side effect reduction | ALB, HEXA, ADAR | KMT2A 996/4885TLR2 1737/4885CASP3 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.